Showing results (31-40 of 400) with videos related to
Sort By:
Pageof 40
Medical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro BarniTranslational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro BarniHead & Neck|September 29, 2011
Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysisFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|December 17, 2010
Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?Fausto Petrelli, Sandro BarniClinical Breast Cancer|January 2, 2013
A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancerFausto Petrelli, Sandro BarniClinical Genitourinary Cancer|October 8, 2013
Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapiesFausto Petrelli, Sandro BarniAnnals of Palliative Medicine|April 6, 2015
The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?Fausto Petrelli, Sandro BarniUrology|February 21, 2016
Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysisFausto Petrelli, Ivano Vavassori, Mary Cabiddu, et al.Pageof 40